Research
Hormonal
Short-chain fatty acids (SCFAs), particularly butyrate, produced by gut microbiota fermentation of prebiotics/probiotics, improve insulin sensitivity by activating G-protein-coupled receptors on L-cells to stimulate GLP-1 and PYY release.
Eating prebiotic fibers (like those in chicory, onions, garlic) feeds gut bacteria that produce SCFAs like butyrate. These SCFAs signal your gut to release hormones (GLP-1, PYY) that help regulate blood sugar and appetite.
GoodSupportsHIGH confidence
Activation of G-protein-coupled receptors on L-cells by SCFA promotes the release of glucagon-like peptide-1 and peptide YY resulting in increased insulin and decreased glucagon secretion, and suppressed appetite.
Why this rating
Supported by multiple animal studies and some human data cited in the review, establishing a clear biological pathway.
Source
Probiotics, prebiotics, synbiotics and insulin sensitivity
Y. A. Kim et al. · Nutrition Research Reviews · 2017
DOI 10.1017/s095442241700018x
narrative_reviewCited 319×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Administration of probiotics, prebiotics, or synbiotics can improve insulin sensitivity and glucose metabolism in humans, primarily through mechanisms involving short-chain fatty acid (SCFA) production, modulation of gut microbiota composition, and reduction of systemic inflammation.Moderate
- Probiotic supplementation can reduce systemic inflammation and oxidative stress, which are contributors to insulin resistance, by lowering pro-inflammatory cytokines and increasing antioxidant enzyme activity.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →